Helix BioPharma Corp.'s Steve Demas resigned as COO due to personal reasons.
Helix BioPharma COO resigns
A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research
2021 Year in Review: Highlighting Key Investment Banking Trends
Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings
Global M&A By the Numbers: Q3 2021
Helix BioPharma Corp.'s Steve Demas resigned as COO due to personal reasons.